We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

By LabMedica International staff writers
Posted on 18 Jul 2024
Print article
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide. Many adults avoid routine blood tests due to their complexity and the long wait times for results, which can lead to delayed interventions or missed diagnoses, resulting in substantial avoidable costs. Now, a groundbreaking diagnostic platform is set to transform the existing global infrastructure by providing lab-accurate, actionable test results that aid in the early detection and prevention of chronic conditions.

Truvian Health (San Diego, CA, USA) has developed an automated benchtop system that allows simple, accurate, and comprehensive routine blood tests to be conducted directly in clinics, doctor’s offices, and pharmacies. Utilizing patented technologies and intelligent integration, Truvian’s compact device offers a convenient and economical alternative to traditional off-site labs, delivering quick, lab-accurate results from just a small blood sample, and enhancing healthcare decision-making. The Truvian system combines clinical chemistry, immunoassay, and hematology tests in one operation and can simultaneously handle multiple types of assays. Its initial offering, a comprehensive wellness panel, covers over 90% of the most commonly requested routine blood tests, requiring only one tube and 8 drops of blood.

Truvian has shared data from various independent clinical studies showing that its system's results match those from central laboratories across an extensive range of tests. The platform has been tested with over 50,000 samples from approximately 5,000 donors to date, achieving a reliability rate of over 98%. This system’s capability to provide central lab-quality results in any setting could fundamentally change the way chronic diseases are detected and managed. Immediate access to results enables healthcare providers to diagnose and treat patients without delay, enhancing patient involvement in their health decisions and improving outcomes. By consolidating blood diagnostics into a single visit, the platform reduces healthcare costs for both patients and systems, simplifies the monitoring and management of chronic conditions, and promotes healthier, longer lives. Truvian is now working towards securing US Food and Drug Administration (FDA) clearance for its blood testing platform.

“We are on the cusp of delivering what the world needs to counter today’s non-communicable disease burden and unsustainable healthcare costs,” said Jay Srinivasan, chief executive officer of Truvian.

Related Links:
Truvian Health

New
Gold Member
ANCA IFA
Kallestad Autoimmune ANCA IFA Complete Kit
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
IGFBP-1 Rapid Test
AMNISTRIP
New
Human Papillomavirus Test
RealLine HPV HCR Screen Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The integrated optical sensor is capable of detecting dopamine directly from an unprocessed blood sample (Photo courtesy of Professor Debashis Chanda)

Rapid Dopamine Test to Enable Early Detection of Neurological Disorders

Neurotransmitters are essential for regulating neural function and overall well-being in humans and animals, ensuring a balanced hormonal environment for optimal body functioning. Dopamine is particularly... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: The Accelerate WAVE system delivers rapid AST directly from positive blood culture bottles (Photo courtesy of Accelerate Diagnostics)

Rapid Diagnostic System to Deliver Same-Shift Antibiotic Susceptibility Test Results

The World Health Organization estimates that sepsis impacts around 49 million people worldwide each year, resulting in roughly 11 million deaths, with about 1.32 million of these deaths directly linked... Read more

Pathology

view channel
A schematic of the 3D MM imaging experimental setup used in the studies of blood films (Photo courtesy of Ushenko, A.G., et al.; doi.org/10.1038/s41598-024-63816-z)

Novel Light-Based Technique With 90% Accuracy Rate to Revolutionize Cancer Diagnosis

A quicker, cheaper, and less painful cancer detection technique developed using light has the potential to revolutionize cancer diagnosis, early detection, and monitoring. Researchers at Aston Institute... Read more

Industry

view channel
Image: The QIAstat-Dx IVD panel for neurodegenerative applications will be integrated with the QIAstat-Dx multiplex testing platform (Photo courtesy of QIAGEN)

Qiagen and Eli Lilly to Develop First QIAstat-Dx IVD Panel for Neurodegenerative Applications

QIAGEN N.V. (Venlo, the Netherlands) has entered into a collaboration with Eli Lilly and Company (Indianapolis, IN, USA) to support the development of a QIAstat-Dx in-vitro diagnostic (IVD) to detect APOE genotypes.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.